Compare COHN & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COHN | IGC |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 31.2M |
| IPO Year | N/A | N/A |
| Metric | COHN | IGC |
|---|---|---|
| Price | $17.00 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 41.8K | ★ 933.9K |
| Earning Date | 11-04-2025 | 11-17-2025 |
| Dividend Yield | ★ 6.15% | N/A |
| EPS Growth | ★ 6.29 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $185,475,000.00 | $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | $6.51 | ★ N/A |
| Revenue Growth | ★ 107.11 | N/A |
| 52 Week Low | $6.10 | $0.25 |
| 52 Week High | $20.70 | $0.50 |
| Indicator | COHN | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 39.57 |
| Support Level | $15.23 | $0.29 |
| Resistance Level | $16.98 | $0.36 |
| Average True Range (ATR) | 1.51 | 0.03 |
| MACD | -0.47 | 0.00 |
| Stochastic Oscillator | 32.36 | 25.36 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.